Test Price
8,500 AED✅ Home Collection Available
Can Assist Breast Test in UAE | 8500 AED | DHA Approved
Executive Summary & Core Metrics
Can Assist Breast Test is a prognostic immunohistochemistry assay that stratifies 10‑year recurrence risk for early‑stage, ER‑positive, PR‑positive, HER2‑negative breast cancer patients. This advanced molecular profile guides adjuvant chemotherapy decisions, preventing unnecessary treatments while empowering clinicians with actionable risk data.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing
- Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval (available 8 AM–11 PM)
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
The Can Assist Breast test is a validated immunohistochemistry (IHC)‑based assay combined with Fragment & STR analysis to quantify the expression of key biomarkers. The proprietary algorithm integrates multiple protein expression patterns into a single recurrence risk score, providing oncologists with a reliable decision‑support tool.
| Feature | Can Assist Breast Test (Our Service) | Standard Prognostic Panel |
|---|---|---|
| Precision | Machine‑learning algorithm with IHC quantification | Manual IHC scoring, higher inter‑observer variability |
| Methodology | Immunohistochemistry (IHC) + Fragment & STR Analysis | IHC alone without integrative algorithmic interpretation |
| Turnaround | 15 working days post FFPE block receipt | Often 20–25 working days |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA Registration ID: 61713011) emphasizes: “This test is a powerful decision‑support tool, yet it must always be correlated with full clinical evaluation and multidisciplinary tumour board discussion. Patient empowerment through accurate molecular profiling is our collective responsibility.”
Advisory & Pre-Test Considerations
Important Medication Advisory
Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & Emergency Red Flags
- Must be histologically confirmed invasive breast carcinoma, ER (+), PR (+), HER2 (−).
- Not validated for HER2‑positive or triple‑negative disease.
- Insufficient tumour content in FFPE block (<30% tumour cells) may yield inconclusive results.
- If you experience new breast lump, skin dimpling, persistent bone pain, or severe shortness of breath, seek immediate medical attention – these may indicate progression requiring urgent clinical review.
Patient FAQ & Clinical Guidance
1. What is the Can Assist Breast test and how is it performed?
The Can Assist Breast test is a prognostic immunohistochemistry assay that predicts 10‑year recurrence risk in early‑stage ER+ PR+ HER2‑negative breast cancer patients. In the laboratory, a paraffin‑embedded tumour tissue block is sectioned and stained with specific antibodies; the results are analysed by a proprietary algorithm that integrates multiple protein expression patterns into a single risk score. This score aids oncologists in deciding whether adjuvant chemotherapy may be safely omitted.
2. How do I prepare for the test and what documents are required?
No patient preparation is required beyond the mandatory submission of a duly filled Can Assist Breast Requisition Form alongside the FFPE tissue block. You must ensure the referring oncologist completes the form with accurate clinical and pathological data. Secure Medical Courier retrieval is available from 8 AM to 11 PM; our team will arrange pickup directly from your pathology lab or hospital, maintaining cold‑chain integrity throughout.
3. When will I receive my results and will they be explained to me?
A final validated report is delivered within 15 working days, and you will receive a telephonic clinical guidance session after report issuance. Results include a risk category (low or high) and a personalised recurrence probability. Our DHA‑licensed specialists will interpret the findings and answer your questions, ensuring you fully understand the implications for your treatment plan.
UAE Regulatory & Data Privacy Adherence
Regulatory Framework: This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Laboratory Accreditation: DHA Facility License No. 1143 | ISO 9001:2015 Certified | DNA Labs UAE is the sole provider of this assay in Dubai Healthcare City.
Clinical & Logistical Metadata
| Test Name | Can Assist Breast Test (Recurrence Risk Stratification for ER+ PR+ HER2- Breast Cancer) |
| Price (AED) | 8,500.00 |
| Turnaround Time | 15 working days from FFPE block receipt |
| Sample Type / Matrix | Archival Tissue Specimen (FFPE Tissue Block) – Hospital Extraction Only. Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Immunohistochemistry (IHC) + Fragment & STR Analysis |
| ICD-10-CM Code | C50.9 (Malignant neoplasm of breast, unspecified) |
| LOINC Code | 94504-9 (Breast cancer recurrence risk score) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians